Metastatic eccrine porocarcinoma: response to docetaxel (Taxotere) chemotherapy.
BACKGROUND
Eccrine porocarcinoma is an uncommon neoplasm of the intra-epidermal sweat gland duct.


METHODS
A case of eccrine porocarcinoma in a female renal transplant patient aged 45 years is described with a review of pertinent literature.


RESULTS
The primary tumour was highly pleomorphic. In places large and small cells merged and focally the former component infiltrated the epidermis in a manner akin to Paget's disease of the breast. The majority of the tumour was high grade; using the modified Bloom and Richardson grading system, usually applied to mammary ductal carcinomas, the tumour graded as 3. Metastatic disease developed nine months following primary surgical treatment. The metastatic eccrine porocarcinoma was resistant to epirubicin but responded to docetaxel chemotherapy.


CONCLUSIONS
There are no data to support the use of adjuvant therapy in the management of eccrine porocarcinoma. The use of the modified Bloom and Richardson grading system may define cases at high risk of relapse in which adjuvant therapy might be considered. Metastatic eccrine porocarcinoma has proven resistant to many chemotherapeutic agents. We report the first use of docetaxel in the management of this disease. The treatment was well tolerated and resulted in marked symptomatic and radiological responses. Treatment with docetaxel should be considered in future cases of this rare tumour.
Plunkett
T A
TA
Academic Oncology Unit, Guy's & St. Thomas' Hospitals NHS Trust, Guy's Hospital, London, UK. plunkett@icrf.icnet.uk
Hanby
A M
AM
Miles
D W
DW
Rubens
R D
RD
D018250:Acrospiroma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008875:Middle Aged; D017239:Paclitaxel / Q000031:analogs & derivatives / Q000627:therapeutic use*; D013544:Sweat Gland Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D043823:Taxoids; D013909:Thorax / Q000473:pathology; D014057:Tomography, X-Ray Computed
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel